Actively Recruiting
Evaluating Recombinant Humanized Anti-CD25 Antibody to Prevent Graft-versus-host Disease After Haploidentical or Matched Unrelated Donor Stem Cell Transplant in Children and Young Adults with Transfusion-dependent Thalassemia
Led by Rongrong Liu · Updated on 2024-10-28
396
Participants Needed
5
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of recombinant humanized anti-CD25 monoclonal antibody to prevent graft-versus-host disease GVHD in patients with transfusion-dependent thalassemia undergoing haploidentical or matched unrelated donor hematopoietic stem cell transplantation. GVHD is a major complication that affects the success and quality of life after transplantation. This Phase 2 trial aims to determine whether this antibody reduces GVHD incidence and to assess its safety and impact on quality of life over a two-year follow-up. Participants will be randomly assigned in a 21 ratio to either receive the recombinant humanized anti-CD25 monoclonal antibody combined with standard GVHD prevention or standard prevention alone. The antibody is given in four doses at 1 mgkg on days 7, 14, 28, and 42 after transplantation. The control group will not receive the antibody but will follow the usual GVHD prophylaxis. The study compares outcomes between these two groups. During the study, participants will be monitored for acute GVHD within 100 days and chronic GVHD, overall survival, thalassemia-free survival, transplant-related mortality, complications, infections, immune recovery, quality of life, and adverse events over two years. Regular assessments and follow-ups will evaluate the clinical efficacy and safety of the antibody treatment. The total participation time covers at least two years of follow-up after transplantation.
CONDITIONS
Brief Title
Evaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploidentical/matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Transfusion-dependent Thalassemia
Research Team
R
Rongrong Liu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here